GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Cyclically Adjusted PS Ratio

Aclaris Therapeutics (FRA:8AT) Cyclically Adjusted PS Ratio : 4.09 (As of Jun. 02, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-06-02), Aclaris Therapeutics's current share price is €0.941. Aclaris Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.23. Aclaris Therapeutics's Cyclically Adjusted PS Ratio for today is 4.09.

The historical rank and industry rank for Aclaris Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:8AT' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.55   Med: 4.58   Max: 5.42
Current: 3.93

During the past years, Aclaris Therapeutics's highest Cyclically Adjusted PS Ratio was 5.42. The lowest was 3.55. And the median was 4.58.

FRA:8AT's Cyclically Adjusted PS Ratio is ranked worse than
68.42% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.35 vs FRA:8AT: 3.93

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aclaris Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.031. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.23 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aclaris Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Aclaris Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Cyclically Adjusted PS Ratio Chart

Aclaris Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 4.00

Aclaris Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 4.00 4.73

Competitive Comparison of Aclaris Therapeutics's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Cyclically Adjusted PS Ratio falls into.



Aclaris Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Aclaris Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.941/0.23
=4.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Aclaris Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.031/131.7762*131.7762
=0.031

Current CPI (Mar. 2024) = 131.7762.

Aclaris Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.020 104.136 0.025
201712 0.027 104.011 0.034
201803 0.029 105.290 0.036
201806 0.102 106.317 0.126
201809 0.031 106.507 0.038
201812 0.040 105.998 0.050
201903 0.027 107.251 0.033
201906 0.019 108.070 0.023
201909 0.022 108.329 0.027
201912 0.024 108.420 0.029
202003 0.031 108.902 0.038
202006 0.043 108.767 0.052
202009 0.029 109.815 0.035
202012 0.030 109.897 0.036
202103 0.030 111.754 0.035
202106 0.028 114.631 0.032
202109 0.023 115.734 0.026
202112 0.022 117.630 0.025
202203 0.021 121.301 0.023
202206 0.022 125.017 0.023
202209 0.288 125.227 0.303
202212 0.110 125.222 0.116
202303 0.035 127.348 0.036
202306 0.024 128.729 0.025
202309 0.123 129.860 0.125
202312 0.227 129.419 0.231
202403 0.031 131.776 0.031

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aclaris Therapeutics  (FRA:8AT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Aclaris Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics (FRA:8AT) Business Description

Traded in Other Exchanges
Address
640 Lee Road, Suite 200, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines